Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 141

1.

Inhibition of mammalian target of rapamycin or apoptotic pathway induces autophagy and radiosensitizes PTEN null prostate cancer cells.

Cao C, Subhawong T, Albert JM, Kim KW, Geng L, Sekhar KR, Gi YJ, Lu B.

Cancer Res. 2006 Oct 15;66(20):10040-7.

2.

Autophagy for cancer therapy through inhibition of pro-apoptotic proteins and mammalian target of rapamycin signaling.

Kim KW, Mutter RW, Cao C, Albert JM, Freeman M, Hallahan DE, Lu B.

J Biol Chem. 2006 Dec 1;281(48):36883-90. Epub 2006 Sep 27.

3.

Targeting the Akt/mammalian target of rapamycin pathway for radiosensitization of breast cancer.

Albert JM, Kim KW, Cao C, Lu B.

Mol Cancer Ther. 2006 May;5(5):1183-9.

4.

The combination of RAD001 and MK-2206 exerts synergistic cytotoxic effects against PTEN mutant gastric cancer cells: involvement of MAPK-dependent autophagic, but not apoptotic cell death pathway.

Ji D, Zhang Z, Cheng L, Chang J, Wang S, Zheng B, Zheng R, Sun Z, Wang C, Zhang Z, Liu R, Zhang X, Liu X, Wang X, Li J.

PLoS One. 2014 Jan 9;9(1):e85116. doi: 10.1371/journal.pone.0085116. eCollection 2014.

5.

Autophagy upregulation by inhibitors of caspase-3 and mTOR enhances radiotherapy in a mouse model of lung cancer.

Kim KW, Hwang M, Moretti L, Jaboin JJ, Cha YI, Lu B.

Autophagy. 2008 Jul;4(5):659-68. Epub 2008 Apr 7.

6.

Pentagalloylglucose induces autophagy and caspase-independent programmed deaths in human PC-3 and mouse TRAMP-C2 prostate cancer cells.

Hu H, Chai Y, Wang L, Zhang J, Lee HJ, Kim SH, Lü J.

Mol Cancer Ther. 2009 Oct;8(10):2833-43. doi: 10.1158/1535-7163.MCT-09-0288.

8.

PTEN deficiency is associated with reduced sensitivity to mTOR inhibitor in human bladder cancer through the unhampered feedback loop driving PI3K/Akt activation.

Seront E, Pinto A, Bouzin C, Bertrand L, Machiels JP, Feron O.

Br J Cancer. 2013 Sep 17;109(6):1586-92. doi: 10.1038/bjc.2013.505. Epub 2013 Aug 29.

9.

Effect of rapamycin, an mTOR inhibitor, on radiation sensitivity of lung cancer cells having different p53 gene status.

Nagata Y, Takahashi A, Ohnishi K, Ota I, Ohnishi T, Tojo T, Taniguchi S.

Int J Oncol. 2010 Oct;37(4):1001-10.

PMID:
20811722
10.

Enhanced radiation damage of tumor vasculature by mTOR inhibitors.

Shinohara ET, Cao C, Niermann K, Mu Y, Zeng F, Hallahan DE, Lu B.

Oncogene. 2005 Aug 18;24(35):5414-22.

PMID:
15940265
11.

Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells.

Grünwald V, DeGraffenried L, Russel D, Friedrichs WE, Ray RB, Hidalgo M.

Cancer Res. 2002 Nov 1;62(21):6141-5.

12.

mTOR inhibitor RAD001 (everolimus) induces apoptotic, not autophagic cell death, in human nasopharyngeal carcinoma cells.

Cai Y, Xia Q, Su Q, Luo R, Sun Y, Shi Y, Jiang W.

Int J Mol Med. 2013 Apr;31(4):904-12. doi: 10.3892/ijmm.2013.1282. Epub 2013 Feb 21.

PMID:
23426850
13.

PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs.

Weigelt B, Warne PH, Downward J.

Oncogene. 2011 Jul 21;30(29):3222-33. doi: 10.1038/onc.2011.42. Epub 2011 Feb 28.

PMID:
21358673
14.

Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro.

Liu H, Scholz C, Zang C, Schefe JH, Habbel P, Regierer AC, Schulz CO, Possinger K, Eucker J.

Anticancer Res. 2012 May;32(5):1627-37.

PMID:
22593441
15.

Inhibition of autophagy as a strategy to augment radiosensitization by the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.

Cerniglia GJ, Karar J, Tyagi S, Christofidou-Solomidou M, Rengan R, Koumenis C, Maity A.

Mol Pharmacol. 2012 Dec;82(6):1230-40. doi: 10.1124/mol.112.080408. Epub 2012 Sep 18.

16.

MYC activity mitigates response to rapamycin in prostate cancer through eukaryotic initiation factor 4E-binding protein 1-mediated inhibition of autophagy.

Balakumaran BS, Porrello A, Hsu DS, Glover W, Foye A, Leung JY, Sullivan BA, Hahn WC, Loda M, Febbo PG.

Cancer Res. 2009 Oct 1;69(19):7803-10. doi: 10.1158/0008-5472.CAN-09-0910. Epub 2009 Sep 22.

17.

The role of mTOR inhibition in augmenting radiation induced autophagy.

Jaboin JJ, Shinohara ET, Moretti L, Yang ES, Kaminski JM, Lu B.

Technol Cancer Res Treat. 2007 Oct;6(5):443-7. Review.

PMID:
17877432
18.

PTEN loss does not predict for response to RAD001 (Everolimus) in a glioblastoma orthotopic xenograft test panel.

Yang L, Clarke MJ, Carlson BL, Mladek AC, Schroeder MA, Decker P, Wu W, Kitange GJ, Grogan PT, Goble JM, Uhm J, Galanis E, Giannini C, Lane HA, James CD, Sarkaria JN.

Clin Cancer Res. 2008 Jun 15;14(12):3993-4001. doi: 10.1158/1078-0432.CCR-07-4152.

19.

PKB/Akt mediates radiosensitization by the signaling inhibitor LY294002 in human malignant gliomas.

Nakamura JL, Karlsson A, Arvold ND, Gottschalk AR, Pieper RO, Stokoe D, Haas-Kogan DA.

J Neurooncol. 2005 Feb;71(3):215-22.

PMID:
15735908
20.

mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways.

Majumder PK, Febbo PG, Bikoff R, Berger R, Xue Q, McMahon LM, Manola J, Brugarolas J, McDonnell TJ, Golub TR, Loda M, Lane HA, Sellers WR.

Nat Med. 2004 Jun;10(6):594-601. Epub 2004 May 23.

PMID:
15156201

Supplemental Content

Support Center